Danaher (NYSE:DHR) Posts Earnings Results, Meets Estimates

Danaher (NYSE:DHR) announced its quarterly earnings data on Wednesday. The conglomerate reported $2.14 EPS for the quarter, meeting the consensus estimate of $2.14, RTT News reports. Danaher had a net margin of 16.39% and a return on equity of 10.62%. During the same period in the previous year, the business earned $2.09 earnings per share.

Danaher Stock Performance

Shares of DHR stock opened at $233.34 on Wednesday. Danaher has a one year low of $225.42 and a one year high of $281.70. The company has a 50 day moving average price of $236.09 and a 200 day moving average price of $253.66. The firm has a market capitalization of $168.54 billion, a price-to-earnings ratio of 44.65, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be issued a dividend of $0.27 per share. The ex-dividend date is Friday, December 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.46%. Danaher’s payout ratio is currently 20.61%.

Analyst Upgrades and Downgrades

DHR has been the topic of several research analyst reports. Guggenheim initiated coverage on Danaher in a research note on Thursday, December 19th. They set a “buy” rating and a $275.00 price target on the stock. Scotiabank initiated coverage on Danaher in a research report on Monday, December 23rd. They set a “sector perform” rating and a $265.00 target price on the stock. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. Royal Bank of Canada lowered their price objective on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. Finally, Stephens restated an “overweight” rating and set a $315.00 target price on shares of Danaher in a research report on Wednesday, October 23rd. Six research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $285.81.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.